Rhythm (RYTM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$239.9M

Revenue (quarter)

$71.3M

Revenue growth (year over year)

+46.91%

Gross profit (trailing twelve months)

$213.5M

Gross margin

89.00%

Net income (trailing twelve months)

−$205.3M

Net income (quarter)

−$49.3M

Net income growth (year over year)

−5.72%

Net margin

−85.59%

Return on equity

−204.70%

EPS (trailing twelve months)

−$3.12

Book value per share

$3.16

P/E (trailing twelve months)

—

Price to book

28.06

Debt to assets

50.30%

Payout ratio

—

Dividend yield

—

Company profile

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

• Is Rhythm (RYTM) profitable?

  No. Rhythm reported a net loss of $205.3M over the trailing twelve months.

• How much revenue does Rhythm (RYTM) make?

  Rhythm generated $239.9M in revenue over the trailing twelve months, up 46.91% year over year.

• How do I buy stock in Rhythm (RYTM)?

  RYTM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.